The advisory panel first voted, with one abstention, to back the usual U.S. recommendation that nearly everyone age 6 months ...

While positive, results from a late-stage clinical trial appear to be raising questions about how useful the company’s ...

The esketamine nasal spray – sold as Spravato by Johnson & Johnson – is the first new class of depression drug subsidised by the Pharmaceutical Benefits Scheme in more than 30 years.

After it was approved in 2019, Spravato, a depression treatment derived from the club drug ketamine, was looking like a dud. But recently it has taken off, and it surpassed $1 billion in annual ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a ...

Spravato is a ketamine-derived nasal spray that is FDA-approved for treatment-resistant depression. The Johnson & Johnson drug has been on the market since 2019 , but could only be prescribed ...

A study by Johnson & Johnson, the company that makes Spravato, showed that 22.5% of people using esketamine nasal spray achieved remission from major depression in four weeks. Just 7.6% of people ...

Spravato nasal spray is administered by the patient under the supervision of a health care provider in a ... Approval of Spravato was granted to Johnson & Johnson. More Information. Related News. ...

Johnson & Johnson's Spravato nasal spray okayed as stand-alone treatment for depression. By HT News Desk, New Delhi. Jan 23, 2025 03:21 PM IST . Share Via. Copy Link.

Major depressive disorder affects an estimated 8.3% of the adult population. And now there’s a new option for treatment: Spravato, a nasal spray that’s been shown to give rapid relief to depression ...

Major depressive disorder affects an estimated 8.3% of the adult population. And now there’s a new option for treatment: Spravato, a nasal spray that’s been shown to give rapid relief to ...